Health Care·Pharmaceuticals·$3.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.84 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and did not offer specific guidance for the future. They emphasized the importance of their ongoing projects.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on advancing their product pipeline despite current financial challenges.
Liquidia Corp's disappointing earnings report, particularly the negative EPS, led to a significant drop in stock price. The lack of revenue figures and guidance may have contributed to investor uncertainty. Moving forward, the company will need to address its financial challenges while continuing to focus on its product development efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Oct 29, 2018